Alnylam Pharmaceuticals (ALNY) Interest Expenses (2011 - 2026)

Alnylam Pharmaceuticals' Interest Expenses history runs 14 years deep, the most recent figure standing at $69.3 million for Q1 2026.

• Quarterly Interest Expenses rose 0.52% year-over-year to $69.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $154.0 million (down 30.98% YoY) and the FY2025 annual result came in at $252.6 million, down 90.94% from the prior year.
• Interest Expenses was $69.3 million for Q1 2026 at Alnylam Pharmaceuticals, up from $100000.0 in the prior quarter.
• Across five years, Interest Expenses topped out at $94.5 million in Q4 2023 and bottomed at -$83.0 million in Q4 2022.
• A 5-year average of $37.6 million and a median of $40.2 million in 2025 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2022 — Interest Expenses sank 325.32% — and 2023, when it jumped 213.97%.
• Alnylam Pharmaceuticals' Interest Expenses stood at -$83.0 million in 2022, then soared by 213.97% to $94.5 million in 2023, then slipped by 8.39% to $86.6 million in 2024, then slumped by 99.88% to $100000.0 in 2025, then soared by 69186.0% to $69.3 million in 2026.
• Business Quant data shows ALNY's Interest Expenses at $69.3 million in Q1 2026, $100000.0 in Q4 2025, and $44.4 million in Q3 2025.